Atricure, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023 and Provides Financial Guidance for the Year 2024
January 08, 2024 at 08:00 am EST
Share
AtriCure, Inc. provided revenue guidance for the fourth quarter and Full Year of 2023 and provided financial guidance for the year 2024. Preliminary, unaudited revenue for fourth quarter 2023 is expected to be $106.5 million, reflecting growth of approximately 21% over the fourth quarter of 2022 (20% on a constant currency basis). U.S. revenue is expected to be $88.7 million, reflecting growth of approximately 20%, and international revenue is expected to be $17.8 million, an increase of approximately 26% as reported (22% on a constant currency basis). Fourth quarter revenue was driven by strong growth in Hybrid AF? therapy, followed by sales of AtriClip®, Encompass®, and cryoSPHERE® devices.
Preliminary, unaudited revenue for full year 2023 is expected to be $399.2 million, reflecting growth of approximately 21% over full year 2022 (21% on a constant currency basis).
Management projects 2024 revenue of approximately $459 million to $466 million, reflecting growth of approximately 15% to 17% over full year 2023.
AtriCure, Inc. provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The Company's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.
ATRICURE, INC. 
